Nanoparticles News and Research

RSS

Novel nano-carrier platform shows promise for cancer drug delivery

A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published online in Angewandte Chemie, a leading international chemistry journal.

20 Jan 2012

Scientists use gold-filled silicon wafers to target and burn breast cancer cells

By shining infrared light on specially designed, gold-filled silicon wafers, scientists at The Methodist Hospital Research Institute have successfully targeted and burned breast cancer cells. If the technology is shown to work in human clinical trials, it could provide patients a non-invasive alternative to surgical ablation, and could be used in conjunction with traditional cancer treatments, such as chemotherapy, to make those treatments more effective.

18 Jan 2012

Smart injectable nanotherapeutics could improve treatment for Type I diabetes

A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children's Hospital Boston has developed "smart" injectable nanotherapeutics that can be programmed to selectively deliver drugs to the cells of the pancreas. Although this nanotechnology will need significant additional testing and development before being ready for clinical use, it could potentially improve treatment for Type I diabetes by increasing therapeutic efficacy and reducing side effects.

13 Jan 2012

Novel nanosensors can lead to fewer experiments on animals

Countless mice, rats and rabbits die every year in the name of science - and the situation is getting worse. While German laboratories used some 2.41 million animals for scientific research in 2005, by 2009 this number had grown to 2.79 million. One third were destined for fundamental biology research, and the majority were used for researching diseases and developing medical compounds and devices.

11 Jan 2012

Bladder cancer is one of the top 10 most common forms of cancer in the US

Bladder cancer, most frequently caused by smoking and exposure to carcinogens in the workplace, is one of the top 10 most common forms of cancer in men and women in the U.S. More than 70 percent of bladder cancers are diagnosed in stage T1 or less and have not invaded the muscle layer.

11 Jan 2012

ORMOSIL nanoparticles show promise as potential drug delivery vehicle

In the images of fruit flies, clusters of neurons are all lit up, forming a brightly glowing network of highways within the brain. It's exactly what University at Buffalo researcher Shermali Gunawardena was hoping to see: It meant that ORMOSIL, a novel class of nanoparticles, had successfully penetrated the insects' brains. And even after long-term exposure, the cells and the flies themselves remained unharmed.

10 Jan 2012

Researchers create prostate cancer drug delivery system

Honing chemotherapy delivery to cancer cells is a challenge for many researchers. Getting the cancer cells to take the chemotherapy "bait" is a greater challenge. But perhaps such a challenge has not been met with greater success than by the nanotechnology research team of Omid Farokhzad, MD, Brigham and Women's Hospital (BWH) Department of Anesthesiology Perioperative and Pain Medicine and Research.

10 Jan 2012

Novel class of nanoparticles hold promise as a potential vehicle for drug delivery

In the images of fruit flies, clusters of neurons are all lit up, forming a brightly glowing network of highways within the brain. It’s exactly what University at Buffalo researcher Shermali Gunawardena was hoping to see: It meant that ORMOSIL, a novel class of nanoparticles, had successfully penetrated the insects’ brains. And even after long-term exposure, the cells and the flies themselves remained unharmed.

9 Jan 2012

Clearside Biomedical receives $4M venture capital investment

Technology developed by researchers at the Georgia Institute of Technology and Emory University for delivering drugs and other therapeutics to specific locations in the eye provides the foundation for a startup company that has received a $4 million venture capital investment.

6 Jan 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

Midatech raises £6.3M through private investment round

Midatech Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, announced today it has raised £6.3 million through a private investment round.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Glycol chitosan-coated MRI agent safer, more effective in detecting breast cancer

Many imaging technologies and their contrast agents - chemicals used during scans to help detect tumors and other problems - involve exposure to radiation or heavy metals, which present potential health risks to patients and limit the ways they can be applied.

26 Dec 2011

New pharma title from iSmithers ‘Update on Polymers for Ocular Drug Delivery’

The eye is the most easily accessible site for topical administration of a medication. Drugs are commonly applied to the eye for localised action on the surface or in the interior of the eye. A major problem in ocular therapeutics is the attainment of an optimal drug concentration at the site of action.

21 Dec 2011

Gene therapy may promote growth of hair cells in inner ear

Normal hearing depends on the presence of healthy hair cells in the inner ear. Gene therapy has the potential to slow the loss of hair cells and promote the growth of hair cells that have already been damaged.

20 Dec 2011

Researchers demonstrate laser transmission spectroscopy

A team of researchers from the University of Notre Dame have demonstrated a novel DNA detection method that could prove suitable for many real-world applications.

17 Dec 2011

Dendrimers offers a new way to treat age-related macular degeneration, retinitis pigmentosa

Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A study by investigators at Mayo Clinic, Wayne State University and Johns Hopkins Medicine shows that steroids attached to the dendrimers target the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.

14 Dec 2011

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.

14 Dec 2011

Synthetic human tissue aids in testing photoacoustic and ultrasonic imaging technologies

The precise blending of tiny particles and multicolor dyes transforms gelatin into a realistic surrogate for human tissue. These tissue mimics, known as "phantoms," provide an accurate proving ground for new photoacoustic and ultrasonic imaging technologies.

1 Dec 2011

Harvard SEAS, BASF to co-host symposium on pharmaceutical nanoformulations

From targeted cancer chemotherapy to the guarantee of successful organ transplants, the 21st century may prove to be the age of big ideas in medicine. The drugs themselves, though, will be miniscule. Experts in chemistry, applied physics, materials science, and pharmaceutical science are gathering this week for the BASF Advanced Research Initiative at Harvard University's symposium on pharmaceutical nanoformulations.

1 Dec 2011